100 related articles for article (PubMed ID: 18927120)
1. Sirolimus interacts with pathways essential for podocyte integrity.
Letavernier E; Bruneval P; Vandermeersch S; Perez J; Mandet C; Belair MF; Haymann JP; Legendre C; Baud L
Nephrol Dial Transplant; 2009 Feb; 24(2):630-8. PubMed ID: 18927120
[TBL] [Abstract][Full Text] [Related]
2. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes.
Vollenbröker B; George B; Wolfgart M; Saleem MA; Pavenstädt H; Weide T
Am J Physiol Renal Physiol; 2009 Feb; 296(2):F418-26. PubMed ID: 19019920
[TBL] [Abstract][Full Text] [Related]
3. GSK3β inactivation in podocytes results in decreased phosphorylation of p70S6K accompanied by cytoskeletal rearrangements and inhibited motility.
George B; Vollenbröker B; Saleem MA; Huber TB; Pavenstädt H; Weide T
Am J Physiol Renal Physiol; 2011 May; 300(5):F1152-62. PubMed ID: 21228102
[TBL] [Abstract][Full Text] [Related]
4. Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.
Patek CE; Fleming S; Miles CG; Bellamy CO; Ladomery M; Spraggon L; Mullins J; Hastie ND; Hooper ML
Hum Mol Genet; 2003 Sep; 12(18):2379-94. PubMed ID: 12915483
[TBL] [Abstract][Full Text] [Related]
5. High sirolimus levels may induce focal segmental glomerulosclerosis de novo.
Letavernier E; Bruneval P; Mandet C; Duong Van Huyen JP; Péraldi MN; Helal I; Noël LH; Legendre C
Clin J Am Soc Nephrol; 2007 Mar; 2(2):326-33. PubMed ID: 17699432
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival.
Eremina V; Cui S; Gerber H; Ferrara N; Haigh J; Nagy A; Ema M; Rossant J; Jothy S; Miner JH; Quaggin SE
J Am Soc Nephrol; 2006 Mar; 17(3):724-35. PubMed ID: 16436493
[TBL] [Abstract][Full Text] [Related]
7. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome.
Schumacher VA; Jeruschke S; Eitner F; Becker JU; Pitschke G; Ince Y; Miner JH; Leuschner I; Engers R; Everding AS; Bulla M; Royer-Pokora B
J Am Soc Nephrol; 2007 Mar; 18(3):719-29. PubMed ID: 17267748
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins.
Stallone G; Infante B; Pontrelli P; Gigante M; Montemurno E; Loverre A; Rossini M; Schena FP; Grandaliano G; Gesualdo L
Transplantation; 2011 May; 91(9):997-1004. PubMed ID: 21364499
[TBL] [Abstract][Full Text] [Related]
9. Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy.
Sakurai N; Kuroiwa T; Ikeuchi H; Hiramatsu N; Takeuchi S; Tomioka M; Shigehara T; Maeshima A; Kaneko Y; Hiromura K; Kopp JB; Nojima Y
Nephrol Dial Transplant; 2009 Aug; 24(8):2378-83. PubMed ID: 19188342
[TBL] [Abstract][Full Text] [Related]
10. Post-transplantation proteinuria and sirolimus.
Izzedine H; Brocheriou I; Frances C
N Engl J Med; 2005 Nov; 353(19):2088-9. PubMed ID: 16282189
[No Abstract] [Full Text] [Related]
11. 1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway.
Xiao H; Shi W; Liu S; Wang W; Zhang B; Zhang Y; Xu L; Liang X; Liang Y
Am J Nephrol; 2009; 30(1):34-43. PubMed ID: 19202327
[TBL] [Abstract][Full Text] [Related]
12. An inducible mouse model for PAX2-dependent glomerular disease: insights into a complex pathogenesis.
Wagner KD; Wagner N; Guo JK; Elger M; Dallman MJ; Bugeon L; Schedl A
Curr Biol; 2006 Apr; 16(8):793-800. PubMed ID: 16631587
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin promotes podocyte migration through the up-regulation of urokinase receptor.
Wu MJ; Chang CH; Shu KH; Ho HC; Li JR; Fu YC
Transplant Proc; 2014 May; 46(4):1226-8. PubMed ID: 24815166
[TBL] [Abstract][Full Text] [Related]
14. mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
Letavernier E; Legendre C
Transplant Rev (Orlando); 2008 Apr; 22(2):125-30. PubMed ID: 18631865
[TBL] [Abstract][Full Text] [Related]
15. Cystinosin deficiency causes podocyte damage and loss associated with increased cell motility.
Ivanova EA; Arcolino FO; Elmonem MA; Rastaldi MP; Giardino L; Cornelissen EM; van den Heuvel LP; Levtchenko EN
Kidney Int; 2016 May; 89(5):1037-1048. PubMed ID: 27083281
[TBL] [Abstract][Full Text] [Related]
16. Parietal podocytes in normal human glomeruli.
Bariety J; Mandet C; Hill GS; Bruneval P
J Am Soc Nephrol; 2006 Oct; 17(10):2770-80. PubMed ID: 16943305
[TBL] [Abstract][Full Text] [Related]
17. The podocyte as a direct target of immunosuppressive agents.
Schönenberger E; Ehrich JH; Haller H; Schiffer M
Nephrol Dial Transplant; 2011 Jan; 26(1):18-24. PubMed ID: 20937691
[TBL] [Abstract][Full Text] [Related]
18. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats.
Fujimura T; Yamagishi S; Ueda S; Fukami K; Shibata R; Matsumoto Y; Kaida Y; Hayashida A; Koike K; Matsui T; Nakamura K; Okuda S
Nephrol Dial Transplant; 2009 May; 24(5):1397-406. PubMed ID: 19042927
[TBL] [Abstract][Full Text] [Related]
19. Cellular effects of everolimus and sirolimus on podocytes.
Müller-Krebs S; Weber L; Tsobaneli J; Kihm LP; Reiser J; Zeier M; Schwenger V
PLoS One; 2013; 8(11):e80340. PubMed ID: 24260371
[TBL] [Abstract][Full Text] [Related]
20. The spectrum of focal segmental glomerulosclerosis: new insights.
D'Agati VD
Curr Opin Nephrol Hypertens; 2008 May; 17(3):271-81. PubMed ID: 18408478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
